BAYN Bayer Aktiengesellschaft

Bayer has delivered a sharp share price recovery over the past year, which puts fresh attention on a simple question about the stock: Are investors now paying a price that still lines up with what the business generates in sales? Bayer’s 83.8% 1 year return puts a lot of recent optimism on trial against what the company’s revenue base can realistically support. New U.S. regulatory milestones for therapies like Lynkuet for vasomotor symptoms in breast cancer patients and KERENDIA for chronic...

Bayer (XTRA:BAYN) said the U.S. FDA has accepted a supplemental New Drug Application for Lynkuet (elinzanetant) for review. The filing covers moderate to severe vasomotor symptoms in women receiving endocrine therapy for hormone receptor-positive breast cancer. The FDA granted priority review status, indicating an accelerated assessment timeline compared with a standard review process. The priority review for Lynkuet in endocrine therapy related vasomotor symptoms is only one part of the...

If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.

Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% report

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.

Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.

Bayer (XTRA:BAYN) just received accelerated FDA approval for sevabertinib as a first-line therapy for certain HER2-mutant lung cancer patients, which puts a fresh spotlight on how its pharmaceutical pipeline might influence investor sentiment. Against that backdrop, Bayer shares have climbed strongly this year. The 90 day share price return is 31.84% and the year to date share price return is 28.89%, while the 1 year total shareholder return of 79.40% suggests recent momentum has followed a...

A Missouri judge will weigh the deal against objections from plaintiffs' attorneys who say the framework shortchanges their clients

By Dietrich Knauth NEW YORK, Sept 11 (Reuters) - Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of

BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.

With a big redesign, will people still give their best? The answer depends on what you believe about your people.

For investors, there are many ways to play commodities, including exchange-traded funds keyed off agricultural commodities and food-related stocks.

Bayer Aktiengesellschaft (ETR:BAYN) outlined progress on its Crop Science division’s five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s clean EBITDA margin and more than €3 billion in free operating cash flow by 2029. Rodrigo Santos,

Bayer (XTRA:BAYN) is back in focus after detailed Phase III REVEAL data for its investigational PET radiotracer iodine 124 evuzamitide in cardiac amyloidosis were presented, meeting predefined diagnostic accuracy endpoints. The REVEAL data arrive after a period of strong share price momentum for Bayer, with the 90 day share price return of 40.86% and year to date share price return of 28.63%, which contrasts with a three year total shareholder return that is slightly negative. Extend this...